{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:33:01Z","timestamp":1790371981724,"version":"4.1.0"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016087"],"award-info":[{"award-number":["P30CA016087"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0699-5","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T13:02:39Z","timestamp":1566219759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients"],"prefix":"10.1136","volume":"7","author":[{"given":"Douglas","family":"Donnelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Balar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"issue":"8","key":"699_CR1","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"J Gershenwald","year":"2018","unstructured":"Gershenwald J, Scolyer R, et al. Melanoma staging: American joint committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105\u201310.","journal-title":"Ann Surg Oncol"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-018-0397-8","volume":"6","author":"M Albertini","year":"2018","unstructured":"Albertini M. The age of enlightenment in melanoma immunotherapy. J Immunother Cancer. 2018;6:80.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"699_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/jdv.12515","volume":"29","author":"F Skowron","year":"2015","unstructured":"Skowron F, Berard F, Balme B, Maucort-Boulch D. Role of obesity on the thickness of primary cutaneous melanoma. J Eur Acad Dermatol Venerol. 2015;29(2):262\u20139.","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"699_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ejca.2012.08.028","volume":"49","author":"TN Sergentanis","year":"2013","unstructured":"Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies. Eur J Cancer. 2013;49:642\u201357.","journal-title":"Eur J Cancer"},{"issue":"3","key":"699_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"J McQuade","year":"2018","unstructured":"McQuade J, Daniel C, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310\u201322.","journal-title":"Lancet Oncol"},{"key":"699_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","volume":"25","author":"Z Wang","year":"2019","unstructured":"Wang Z, Aguilar E, Luna J, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25:141\u201351.","journal-title":"Nat Med"},{"key":"699_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","volume":"7","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7:57.","journal-title":"J Immunother Cancer"},{"key":"699_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","volume":"7","author":"G Naik","year":"2019","unstructured":"Naik G, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019;7:89.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"699_CR9","doi-asserted-by":"publisher","first-page":"e0204729","DOI":"10.1371\/journal.pone.0204729","volume":"13","author":"G Richtig","year":"2018","unstructured":"Richtig G, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-Centre study. PLoS One. 2018;13(10):e0204729.","journal-title":"PLoS One"},{"issue":"9","key":"699_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/imt-2018-0053","volume":"10","author":"EE Rassy","year":"2018","unstructured":"Rassy EE, et al. Do immune checkpoint inhibitors perform identically in patients with weight extremes? Immunotherapy. 2018;10(9):733\u20136.","journal-title":"Immunotherapy"},{"key":"699_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633.","journal-title":"Clin Pharmacokinet"},{"key":"699_CR12","doi-asserted-by":"publisher","first-page":"6184","DOI":"10.3390\/ijms15046184","volume":"15","author":"U Jung","year":"2014","unstructured":"Jung U, Choi M. Obesity and its metabolic complications: the role of Adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184\u2013223.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"699_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, et al. Model-based characterization of the pharmacokinetics of Pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):49\u201357.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"699_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"J Wolchok","year":"2017","unstructured":"Wolchok J, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356.","journal-title":"N Engl J Med"},{"issue":"5","key":"699_CR15","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/cncr.32160","volume":"125","author":"D Pulte","year":"2019","unstructured":"Pulte D, et al. Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. Cancer. 2019;125(5):2656\u201365.","journal-title":"Cancer"},{"issue":"2","key":"699_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/dom.12124","volume":"16","author":"SK Garg","year":"2014","unstructured":"Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab. 2014;16(2):97\u2013110.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"699_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1161\/01.HYP.0000052314.95497.78","volume":"41","author":"J Hall","year":"2003","unstructured":"Hall J. The kidney, hypertension, and obesity. Hypertension. 2003;41(3):625\u201333.","journal-title":"Hypertension"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0699-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0699-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0699-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:07:11Z","timestamp":1695107231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0699-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0699-5","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient data used in this manuscript comes from patients that were prospectively enrolled in the NYU Interdisciplinary Melanoma Cooperative Group (IMCG), which has been in existence since 2002. Biospecimens, clinicopathological data, and follow-up information are collected using developed protocols and Standard Operating Procedure (SOP). Upon consent, each patient is assigned a unique identification number. From review of patients\u2019 medical records, trained data managers capture clinical and pathological information in 335 fields in the REDCap database. Physicians in the NYU Departments of Dermatology, Pathology, Surgery, and Oncology, as well as Biostatisticians, were involved in the design of the database and the definitions of the data collection fields. Demographic background, personal and family history of disease, pathological diagnoses, radiological imaging reports, sentinel lymph node mapping, disease staging, treatment, and continuing clinical follow-up information, all compiled from thorough review of medical records and clinician interview, are incorporated into the database. Neither the name nor identifying information for an individual patient is used in program publications.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}